Posted by Michael Wonder on 12 Jun 2018
SMC approves funding for six new therapies on the NHS
12 June 2018 - The Scottish Medicines Consortium has approved NHS funding for six new therapies, offering patients new options for leukaemia, epilepsy, lung cancer, plaque psoriasis, and carcinoid syndrome-related diarrhea.
Pfizer’s Besponsa (inotuzumab ozogamicin) was endorsed for the treatment of acute lymphoblastic leukaemia, a rare, very aggressive and rapidly progressing form of the disease with a particularly poor prognosis.
According to participants of the SMC’s Patient and Clinician Engagement process, chemotherapy is often ineffective and the majority of patients are unable to go on to receive a transplant.
